Search results
Author(s):
Parth Visrodia
,
Aniket S Rali
,
Gabriel Hernandez
,
et al
Added:
3 months ago
Author(s):
Sanjeev Gulati
Added:
2 months ago
Iron Deficiency in LVAD Patients
Author(s):
William Herrik Nielsen
,
Finn Gustafsson
Added:
1 year ago
Article
Timing of Heart Transplantation & LVADs
Video Series
Timing of Heart Transplantation & LVADs
Author(s):
Espeed Khoshbin, Owais Dar,
Start date:
Nov 05, 2024
Broadcast
Author(s):
Finn Gustafsson
Added:
1 year ago
HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two…
View more
Author(s):
Alexander E Sullivan
,
Hannah Granger
,
Leonie Dupuis
,
et al
Added:
11 months ago
Author(s):
Mathieu Echivard
Added:
8 months ago
ESC HFA 25 - The WICD-MI study finds heart failure to be frequent in patients with persistent left ventricular dysfunction after acute myocardial infarction.We are joined onsite by Dr Mathieu Echivard (University Hospital of Nancy, Nancy, FR) to discuss key findings from a study investigating heart failure events in patients with persistent left ventricular dysfunction after acute myocardial…
View more
Author(s):
Harriette Van Spall
,
Mandeep Mehra
Added:
2 years ago
AHA 23 - Investigator, Dr Mandeep R Mehra (Brigham and Women's Hospital and Harvard Medical School, US) is joined by Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the ARIES HM3 trial.ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were…
View more
Author(s):
Christian Sohns
,
Added:
2 years ago
ESC 2023 — We are joined onsite by Prof Christian Sohns and Prof Philipp Sommer (Heart and Diabetes Centre, Bad Oyenhausen, DE) to discuss the findings from the CASTLE-HTx trial (NCT04649801).
CASTLE-HTx (Heart and Diabetes Center North-Rhine Westfalia) aimed to determine if atrial fibrillation ablation has beneficial effects on mortality in patients with end-stage heart failure, who are…
View more
